Undifferentiated connective tissue dysplasia (UCTD) is a genetically determined condition with a progressive course characterized by defects in the fibrous structures and the basic connective tissue substance, leading to impaired formation of organs and systems, which determines the features of the associated pathology, as well as the pharmacokinetics and pharmacodynamics of drugs. In dermatological and cosmetological practice, the issue of UCTD is very topical, as individual external presentations of the connective tissue dysmorphogenesis among young people can reach 85.4%. In recent decades, a real revolution has taken place in aesthetic medicine, which is associated with the emergence of new injectable products, development of hardware, cellular and thread techniques. Every year mew methods of treatment emerge and the existing ones are improved. Statistics of the past years show that minimally invasive non-surgical interventions are becoming more and more popular in all countries, their number significantly exceeds the number of surgical operations. To date, there are 2 groups of methods aimed at collagen stimulation: hardware techniques and injection methods. The effectiveness of the use of polylactic acid drugs as the first-line drugs for the correction of UCTD in order to prevent premature ageing was evaluated in the presented clinical cases. Patients with a cosmetology profile were treated according to the complex protocols that included amino acid replacement therapy, IV therapy, contour correction with drugs containing polylactic acid and hardware techniques (microneedle RF lifting with insulated and non-insulated needles, ultrasonic SMAS lifting, ablative laser techniques, Ipl-therapy). As a result, an algorithm for managing a patient with UCTD was developed in the cosmetology practice. The provided clinical cases show that the detection of signs of UCTD can significantly improve the patient’s quality of life and prevent premature aging.
Currently, psoriasis occupies a leading position in the structure of chronic recurrent dermatological diseases. The modern view on the etiopathogenesis of psoriasis allows us to consider this disease as a systemic, genetically determined, immune-mediated process, which manifests itself not only in the form of damage to the skin, but also leads to the development of various comorbid conditions (lesion of the musculoskeletal system, cardiovascular system, excretory system , metabolic disorders, etc.). This fact radically changes the approach to the treatment of patients with psoriasis, to the selection of a systemic drug. The main points in the management of patients with psoriasis, especially of moderate and severe course: interdisciplinary examination of the patient, prevention of the development of comorbid conditions and irreversible (sometimes disabling) changes in internal organs and systems, timely administration of systemic therapy. The article presents modern aspects of the etiopathogenesis of psoriatic disease, the advantages of genetically engineered biological therapy, and a clinical case of treating a patient with severe psoriasis. A 48-old-patient E. who had been suffering from extensive psoriasis vulgaris for 16 years, which manifested after pregnancy and childbirth, was proscribed the systemic therapy. In July 2022, the patient reported oedema that developed in the lower extremities and face while taking methotrexate, and was examined by a nephrologist. Microalbuminuria nephropathy was diagnosed, which served as a reason for adjusting the systemic therapy for psoriasis. The patient had to be switched to the genetically engineered biological therapy. After 3 subcutaneous injections of netakimab at a dose of 120 mg/week, psoriasis went into a steady-state showing the trend towards a regressing stage. The psoriasis severity index scores decreased by the end of the initiating course of therapy.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.